Skip to main content
Analysis

What Is the DMEPOS Master List?

The DMEPOS Master List identifies Medicare equipment, prosthetics, orthotics, and supplies that CMS has flagged as potentially subject to additional conditions of payment. For providers, understanding what inclusion on the list does—and does not—require is essential to avoiding confusion about prior authorization and ordering requirements. 

Key Takeaways 

  • The Master List is not a list of all Medicare-covered DMEPOS. It identifies items CMS has determined may warrant additional oversight based on cost, utilization, improper payments, fraud concerns, or other program-integrity factors. 

  • Being on the Master List does not automatically trigger additional provider requirements. An item generally must also appear on the applicable Required List before CMS's prior authorization or face-to-face encounter/written order prior to delivery requirements apply. 

  • Master List status does not guarantee Medicare coverage or payment. Providers and suppliers must still verify the applicable coverage, medical necessity, coding, ordering, and documentation requirements for the specific item and beneficiary. 

Clinicians who order durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) for Medicare beneficiaries may encounter a document called the DMEPOS Master List. Despite its name, the Master List is not a list of all Medicare-covered DMEPOS—and appearing on it does not automatically mean an item requires prior authorization. 

The Centers for Medicare & Medicaid Services (CMS) describes the Master List as a library of Medicare Fee-for-Service DMEPOS codes that have been identified as potential program-integrity vulnerabilities.¹ Under federal regulations, items may qualify for the list based on factors such as cost and findings of fraud, unnecessary utilization, or improper payments identified through Government Accountability Office (GAO), Office of Inspector General (OIG), or Comprehensive Error Rate Testing (CERT) data. Items displaying certain aberrant billing patterns may also qualify, and some items are included because federal law already imposes particular requirements.² 

As of April 13, 2026, the Master List contained 530 DMEPOS items.¹ 

What Does Being on the Master List Mean? 

Think of the Master List as a pool from which CMS can select items for additional conditions of Medicare payment. CMS may select an item for one or both of two separate Required Lists: 

  • the Required Prior Authorization List, or 

  • the Required Face-to-Face Encounter and Written Order Prior to Delivery (F2F/WOPD) List.¹,³ 

CMS considers factors including utilization, cost, geographic patterns, emerging vulnerabilities, and operational capabilities when deciding which Master List items should be placed on a Required List.¹ When CMS adds items to a Required List, it provides formal notice before the new requirements take effect.¹,³ 

This distinction is critical: an item’s presence on the Master List alone does not trigger these additional requirements. CMS explicitly states that providers and suppliers do not need to take action simply because an item appears on the Master List; the item must also appear on the applicable Required List.¹ As of April 13, 2026, only 74 of the 530 Master List items are on the Required Prior Authorization List, while 83 are on the Required Face-to-Face Encounter and Written Order Prior to Delivery (F2F/WOPD) List.¹ 

What the Master List Does Not Mean 

For providers, Master List status should not be interpreted as an automatic determination of Medicare coverage or payment. The Master List identifies items that may be selected for additional conditions of payment; it does not replace the Medicare coverage, coding, documentation, or medical-necessity requirements that otherwise apply to a DMEPOS claim. CMS describes prior authorization, when required, as a process for determining whether applicable Medicare coverage, payment, and coding requirements are met before an item is delivered.⁴ 

Likewise, appearing on the Master List does not by itself mean prior authorization is required, nor does it mean that a special face-to-face encounter or written order prior to delivery is required. Those obligations arise when the item is included on the corresponding Required List or when a requirement applies separately under statute.1,3 

Bottom line: When ordering DMEPOS for a Medicare beneficiary, do not stop at the Master List. Determine whether the HCPCS code appears on either Required List and then verify the applicable Medicare coverage, documentation, ordering, coding, and payment requirements. 

References 

  1. Centers for Medicare & Medicaid Services. Master List of Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) items potentially subject to conditions of payment. Accessed August 11, 2026. CMS Master List of DMEPOS Items  

  1. Centers for Medicare & Medicaid Services. Medicare program; end-stage renal disease prospective payment system, payment for renal dialysis services furnished to individuals with acute kidney injury, end-stage renal disease quality incentive program, durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) fee schedule amounts, DMEPOS competitive bidding (CBP) proposed amendments, standard elements for a DMEPOS order, and master list of DMEPOS items potentially subject to a face-to-face encounter and written order prior to delivery and/or prior authorization requirements. Final rule. Fed Regist. 2019;84(217):60648-60715. Codified at 42 CFR §414.234.  

  1. Centers for Medicare & Medicaid Services. Durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) order and face-to-face encounter requirements. Updated March 4, 2026. Accessed August 11, 2026. CMS DMEPOS Order and Face-to-Face Encounter Requirements  

  1. Centers for Medicare & Medicaid Services. Prior authorization process for certain durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) items. Updated May 18, 2026. Accessed August 11, 2026. CMS Prior Authorization Process for Certain DMEPOS Items 

 


© 2026 HMP Global. All Rights Reserved.    
This article is part of the Wound Care Policy News Desk and is not peer reviewed. All information regarding reimbursement, legislation, regulations, policy, and legal proceedings, is provided as a service to our audience. Commercially reasonable efforts have been made to ensure the accuracy of the information within this resource but HMP Global, their employees, their affiliates, contributors, commenters, and reviewers do not represent, guarantee, or warranty that any information provided within this resource is error-free. HMP Global, their employees, their affiliates, contributors, and reviewers disclaim all liability attributable to the use of any information, guidance, or advice contained in this resource. The responsibility for verifying information accuracy for individual use and in individual circumstances lies solely with the audience member. The information in this resource is also not a substitute for legal, medical, or business advice, and is for educational purposes only. Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Wounds or HMP Global, their employees, and affiliates.